Astrotech Corporation — Form 10-Q Summary
Period clarification: The supplied filing is for the quarter ended September 30, 2023 (Astrotech fiscal Q1 2024), not 2022 Q1 as stated in the request metadata. Figures below are in U.S. dollars; financial statement amounts are in thousands unless noted.
Business context and reporting period
Astrotech develops and commercializes mass spectrometry technology through wholly owned businesses: 1st Detect (security and explosives detection), AgLAB (hemp and cannabis processing), and BreathTech (breath-based disease screening). The financial statements are unaudited.
Financial performance and liquidity
| Metric | Q1 FY2024 | Q1 FY2023 |
|---|---|---|
| Revenue | $425 | $38 |
| Gross profit / margin | $183 / 43% | $6 / 16% |
| Operating expenses | $3,518 | $2,771 |
| Operating loss | $(3,335) | $(2,765) |
| Net loss | $(2,912) | $(2,530) |
| Net loss per share | $(1.79) | $(1.57) |
| Operating cash flow | $(3,050) | $(2,441) |
Revenue rose $387, primarily from partial fulfillment of a 17-unit TRACER 1000 order. Gross margin improved with sales mix. R&D increased $743 (65.8%) to $1,872, mainly for added staff, cross-platform technology improvements, and method development; SG&A was essentially unchanged. Other income and expense, net, was $423, compared with $235, reflecting higher income on short-term investments. The effective tax rate was approximately 0%; the filing also reports a $2 tax provision in its MD&A.
At September 30, 2023, cash and cash equivalents were $13.090 million, short-term investments $25.863 million, and working capital approximately $39.6 million. Current assets were $41.830 million and current liabilities $2.248 million. Cash declined $1.118 million during the quarter. Investing activities provided $1.977 million, including $2.001 million of proceeds from short-term investments; financing cash use was $45. Total liabilities were $2.515 million, including $540 thousand of lease liabilities. The 2019 related-party note had been repaid in 2022; no current borrowings are reported in the balance sheet.
Changes, outlook, risks, and unusual items
- Compared with the prior-year quarter, revenue increased substantially, but operating expenses and net loss also rose. Operating cash use increased by $609.
- Management reported no material change to its short- and long-term liquidity expectations from its FY2023 Form 10-K. No specific revenue, earnings, or cash-flow guidance is provided.
- TRACER 1000 had been deployed at about 29 locations in 14 countries. TSA cargo detection testing remains ongoing and delayed; completion is needed for U.S. air-cargo approval.
- AgLAB sales efforts are underway. Management reported field-trial average ending-weight yield improvement of 30%, but commercialization, customer adoption, competition, and hemp/cannabis regulation remain uncertain.
- BreathTech is developing its BreathTest-1000 with Cleveland Clinic research covering several infections; the product remains in development.
- A subsequent event: on November 9, 2023, the company accepted an order for seven TRACER 1000 units from a Romania-based purchaser, scheduled for delivery over the following months. Separately, MD&A describes the earlier 17-unit order and partial fulfillment.
- Key risks include customer and revenue concentration (two customers represented materially all quarterly revenue), TSA and product-development delays, supply-chain constraints and cost inflation, market acceptance, and changing cannabis-related regulation. Management said it could raise instrument prices to offset input-cost inflation but cautioned that prolonged or worsening shortages could harm results.
- The company reported no current litigation, no material off-balance-sheet arrangements, and no material changes to previously disclosed risk factors. Disclosure controls were assessed as effective.
Important facts for investors to verify
- Confirm the requested period: this filing covers September 30, 2023, not 2022 Q1.
- Review the timing, delivery, and collection terms for the 17-unit order and the subsequent seven-unit order, including whether they are separate transactions.
- Track cash burn against cash and short-term investments, and assess how long available liquidity can fund operating and development needs.
- Monitor the TSA certification timeline, AgLAB commercial sales and repeat demand, and progress and validation of BreathTech’s clinical work.
- Assess customer concentration, gross-margin sustainability, and the effect of higher R&D spending and supply-chain costs.